A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT05513703 · TERMINATED
Trial details
- NCT number
- NCT05513703
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-21
- Primary completion
- 2024-10-28
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.